Kura Oncology, Inc.
KURA Real Time Price USDRecent trades of KURA by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Chris Jacobs House / R | Purchase $1,001 - $15,000 | Dec. 12, 2022 |
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by KURA's directors and management
Government lobbying spending instances
Estimated quarterly lobbying spending
New patents grants
-
Patent Title: Macrocyclic compounds and compositions, and methods of preparing and using the same Jun. 25, 2024
-
Patent Title: Methods for treating hematological malignancies and ewing's sarcoma Apr. 02, 2024
-
Patent Title: Substituted inhibitors of menin-mll and methods of use Jun. 13, 2023
-
Patent Title: Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors Jun. 13, 2023
-
Patent Title: Substituted inhibitors of menin-mll and methods of use May. 16, 2023
-
Patent Title: Bridged bicyclic inhibitors of menin-mll and methods of use Jan. 17, 2023
-
Patent Title: Methods and compositions for inhibiting the interaction of menin with mll proteins Jan. 03, 2023
-
Patent Title: Synthesis of tipifarnib Jan. 03, 2023
-
Patent Title: Methods of treating cancer with farnesyltransferase inhibitors Jan. 03, 2023
-
Patent Title: Methods of treating cancer with farnesyltransferase inhibitors Apr. 05, 2022
-
Patent Title: Methods of treating cancer patients with farnesyltransferase inhibitors Dec. 28, 2021
-
Patent Title: Methods of treating cancer patients with farnesyltransferase inhibitors Sep. 21, 2021
-
Patent Title: Methods of treating cancer with farnesyltransferase inhibitors Apr. 20, 2021
-
Patent Title: Methods of treating cancer with farnesyltransferase inhibitors Oct. 20, 2020
-
Patent Title: Substituted inhibitors of menin-mll and methods of use Sep. 22, 2020
-
Patent Title: Bridged bicyclic inhibitors of menin-mll and methods of use Aug. 25, 2020
-
Patent Title: Methods and compositions for inhibiting the interaction of menin with mll proteins Mar. 17, 2020
-
Patent Title: Methods of treating cancer patients with farnesyltransferase inhibitors Nov. 12, 2019
-
Patent Title: Methods of treating cancer with farnesyltransferase inhibitors Oct. 01, 2019
-
Patent Title: Methods of treating cancer patients with farnesyltransferase inhibitors Jul. 02, 2019
-
Patent Title: Inhibitors of erk and methods of use May. 28, 2019
-
Patent Title: Methods of treating cancer patients with farnesyltransferase inhibitors May. 21, 2019
-
Patent Title: Methods and compositions for inhibiting the interaction of menin with mll proteins Jan. 08, 2019
-
Patent Title: Methods of treating cancer with farnesyltransferase inhibitors Nov. 27, 2018
-
Patent Title: Methods and compositions for inhibiting the interaction of menin with mll proteins Sep. 18, 2018
-
Patent Title: Methods of treating cancer patients with farnesyltransferase inhibitors Jul. 17, 2018
-
Patent Title: Methods of treating cancer with farnesyltransferase inhibitors May. 01, 2018
-
Patent Title: Inhibitors of erk and methods of use Apr. 24, 2018
-
Patent Title: Methods of treating cancer patients with farnesyltransferase inhibitors Jul. 18, 2017
-
Patent Title: Inhibitors of erk and methods of use Apr. 18, 2017
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Number of mentions of KURA in WallStreetBets Daily Discussion
Recent insights relating to KURA
Recent picks made for KURA stock on CNBC
ETFs with the largest estimated holdings in KURA
|
Shareholder
|
Shares Held
|
|---|
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view KURA Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.